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INTRODUCTION
The ID (inhibitor of DNA binding) group of proteins comprises
four members in vertebrates (ID1-4) that belong to the basic helix-
loop-helix (bHLH) family of transcription factors. The ID group of
proteins has been reported to promote proliferation and inhibit
differentiation in several cell types (Desprez et al., 1995; Norton
and Atherton, 1998; Morrow et al., 1999; Kondo and Raff, 2000).
For example, ID1 regulates hematopoietic stem cell maintenance
(Jankovic et al., 2007; Perry et al., 2007). The gene encoding ID4
is required for neuroprogenitor cell proliferation and proper
differentiation (Yun et al., 2004; Bedford et al., 2005), and enforced
Id4 expression causes astrocytes to dedifferentiate into neural stem-
like cells (Jeon et al., 2008). Because they lack a DNA-binding
domain at the N-terminus, ID proteins are generally thought to
exert their function by forming heterodimers with other bHLH
proteins, preventing these other proteins from forming
transcriptionally active homodimers or heterodimers with the
ubiquitous E proteins (Perk et al., 2005).
In the mammary gland, ID1 is not detectable in luminal
epithelium during any phase of development (Uehara et al., 2003;
Nair et al., 2010). Id2 is expressed in mammary epithelial cells and
is important for terminal differentiation in cultured mammary
epithelial cells and for mammary gland alveologenesis during
pregnancy (Mori et al., 2000; Parrinello et al., 2001; Itahana et al.,
2003). Id4 is expressed in mammary epithelial cells and basal cells,
as assessed by in situ hybridization (de Candia et al., 2006), and
can be induced by acute progesterone treatment (Fernandez-
Valdivia et al., 2008), but its functions in mammary development
are not known.
In this study, we surveyed the expression pattern of Id4 in
mammary glands at puberty and in adulthood, and studied the
impact of Id4 loss on mammary development. Importantly, we
discovered p38MAPK as a novel target of ID4 functions.
MATERIALS AND METHODS
Animals
Two lines of Id4 knockout mice were used. In one line on the CD1
background, 220 bp in the 3 coding region of Id4 was replaced by a
lacZ/neo cassette, leading to the formation of a fusion protein of the N-
terminal 65 amino acids of ID4 with -galactosidase, with concomitant
deletion of most of the ID4 C-terminus (Bedford et al., 2005). This line was
also backcrossed onto the FVB/N background for a subset of the
experiments. In the second line on the 129SV/C57BL6 background, exons
1 and 2 of Id4 were replaced by a GFP/neo cassette (Yun et al., 2004).
MMTV-Wnt1 transgenic mice (on the FVB background) were purchased
from the Jackson Laboratory. The DsRed.T3 transgenic mice have been
described previously (Vintersten et al., 2004).
Tissue transplantation
The inguinal #4 mammary glands of 3-week-old Rag–/–, 129SV/C57BL6,
or FVB females were cleared of the endogenous epithelium and implanted
with a small piece (1-2 mm in diameter) excised from the inguinal glands
of 12- to 16-week-old donor mice (placed under the UV lamp when DsRed
was present). Tissue pieces prepared from Id4–/– and Id4+/+ donors were
transplanted contralaterally.
Hormone treatment
For treatment with either estrogen or progesterone individually, 10-week-
old Id4-null or wild-type mice (CD1 strain) were ovariectomized. Two
weeks later, they were subcutaneously injected daily for 2 days with
vehicle (sesame oil), -estradiol-3-benzoate (1 g), or progesterone (1 mg;
Sigma) in 100 l sesame oil. For treatment with both hormones, FVB mice
bearing transplants from wild-type or Id4-null mammary fragments (FVB
strain) were subcutaneously injected daily with -estradiol-3-benzoate (1
g) and progesterone (1 mg) for 9 days.
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SUMMARY
The ID family of helix-loop-helix proteins regulates cell proliferation and differentiation in many different developmental
pathways, but the functions of ID4 in mammary development are unknown. We report that mouse Id4 is expressed in cap cells,
basal cells and in a subset of luminal epithelial cells, and that its targeted deletion impairs ductal expansion and branching
morphogenesis as well as cell proliferation induced by estrogen and/or progesterone. We discover that p38MAPK is activated in
Id4-null mammary cells. p38MAPK is also activated following siRNA-mediated Id4 knockdown in transformed mammary cells. This
p38MAPK activation is required for the reduced proliferation and increased apoptosis in Id4-ablated mammary glands. Therefore,
ID4 promotes mammary gland development by suppressing p38MAPK activity.
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In vivo and in vitro experiments using p38MAPK inhibitors
FVB mice bearing transplants of mammary fragments from wild-type or
Id4-null FVB mice were injected subcutaneously with -estradiol-3-
benzoate (1 g) and progesterone (1 mg) daily for 9 days, and on each of
the last 3 days were additionally injected with saline or SB203580
(Promega) or SB239063 (Sigma) at 15 mg per kg body weight. Twenty-
four hours following the final treatment, the mammary transplants were
collected for analysis. For quantitation of cell proliferation (Ki67
immunohistochemistry) or apoptosis (TUNEL), at least 1000 cells were
counted for each section per mouse. For in vitro experiments, these
inhibitors were added to cell culture at a final concentration of 10 M.
BrdU incorporation, tissue collection, histology and whole-mount
analysis
Two hours before euthanasia, BrdU (100 g/g body weight; Sigma) was
injected intraperitoneally into some of the mice for assaying cell
proliferation. Mammary glands were fixed in 10% formalin, embedded in
paraffin, sectioned and stained with Hematoxylin and Eosin (H&E). For
whole-mount analysis, the inguinal mammary glands were fixed in acetic
acid/ethanol for 2-4 hours at room temperature and stained with carmine
alum. Whole-gland -galactosidase staining was performed as described
(Brisken et al., 1999).
Immunohistochemistry, immunoblotting and TUNEL assay
Tissue paraffin sections (3 m) were deparaffinized and heated in a
pressure cooker to 145°C in 0.1 M citric acid (pH 6.0) for 10 minutes to
retrieve antigen epitopes. Immunoperoxidase staining was performed using
the Vectastain Elite ABC System (Vector Laboratories). For
immunoblotting, 50 g protein extracts were separated by SDS-PAGE.
Apoptotic cells were determined by the DeadEnd Fluorometric TUNEL
System (Promega). DAPI counterstain was used to visualize nuclei.
TUNEL-positive cells were scored in at least five fields per section, and at
least 1000 cells were counted for each section per mouse.
Antibodies
Antibodies were against: ID4 (L-20, Santa Cruz Biotech), ID2 (C-20, Santa
Cruz Biotech), keratin 8 (TROMA1, DSHB), keratin 5 (AF138,
Convance), -smooth muscle actin (DAKO), netrin 1 [11760 (Salminen et
al., 2000)], neogenin (H-175, Santa Cruz Biotech), Ki67 (2011-11,
Novacastra), BrdU (Beckon Dickinson), p21 (F-5, Santa Cruz Biotech),
p16 (M-156, Santa Cruz Biotech), cyclin D1 (Ab-4, Neomarkers),
phospho-p38 (AB3828, Upstate), p38 (C-20, Santa Cruz Biotech), p38
(11A5, Invitrogen), p38 (9212, Cell Signaling), phospho-BimEL (AB3579,
Upstate), -casein (H-7, Santa Cruz Biotech), WAP (R-131, Santa Cruz
Biotech), -actin (AC-15, Sigma) and GAPDH (FL-335, Santa Cruz
Biotech).
Luminex bead antibody assay
Mammary glands were ground in a mortar with liquid N2 and dissolved in
MPER lysis buffer containing protease inhibitors (Roche). The samples
were left on a rotator overnight at 4°C, and then homogenized on ice with
a sonicator for 1 minute. The protein supernatant was aliquoted and stored
at –80°C. Protein content was measured using the BCA assay (Pierce). A
total of 65 proteins were assayed by combining multiple Luminex bead kits
(Millipore) according to the manufacturer’s protocols with 25 g protein
per well, in duplicate. The plates were read using the Luminex 200 system
(Luminex Corporation).
Cell culture, transfection and cell proliferation (MTS) assays
ZD2855 tumor cells were established from a mammary tumor from an
MMTV-Wnt1 mouse by culturing dissociated cells in DMEM/F-12
medium supplemented with 2.5% fetal bovine serum, 10 ng/ml epidermal
growth factor, 150 g/ml insulin and 100 units/ml penicillin-streptomycin
at 37°C and 5% CO2. This same medium was used to maintain these cells.
For small interfering RNA (siRNA) transfection, ZD2855 cells were
seeded in the growth medium without penicillin-streptomycin in 6-well
plates. Twenty-four hours later, they were transfected with 100 nM siRNA
oligos in DharmaFECT1 transfection reagent (Dharmacon). The sequences
of siRNA oligos against Id4, p38 and p38 are described in
supplementary material Table S2. Non-targeted ConsiRNA oligos were
siGENOME non-targeting siRNA pool #1 (D-001206-13-05, Dharmacon)
and non-targeting siRNA #2 (AM4613, Ambion). For BrdU incorporation,
BrdU was added to the cell culture medium to a final concentration of 10
M for 10-12 hours, and an FITC-conjugated anti-BrdU mouse
monoclonal antibody (556028, BD Pharmingen) was used for flow
cytometry (FACScan, Becton Dickinson). Cell viability was measured
using the CellTiter 96AQueous One Solution Reagent (Promega).
Quantitative (q) real-time PCR analysis
Primary mammary epithelial cells (MECs) were isolated from 6-week-old
Id4+/+ or Id4–/– mice as described (Shackleton et al., 2006), and total RNA
extracted using the RNeasy Mini Kit (Qiagen). Following reverse
transcription to generate single-stranded cDNA, qPCR was performed
using the SYBR Green-based system on the ABI 7900HT according to the
manufacturer’s instruction (Applied Biosystems). Differences in gene
expression between Id4+/+ and Id4–/– mice were determined by the
quantitative comparative CT method in which keratin 5 served as internal
control. Primers for mouse Id4, p21, p16, cyclin D1 and keratin 5 are
described in supplementary material Table S1.
In vitro colony assay
Mammary epithelial cells (1106) were prepared from 12-week-old Id4+/+
or Id4–/– mice as described (Shackleton et al., 2006). After treatment with
10 g rat -globulin (012-000-002, Jackson Laboratories) and 1 g Fc
(553142, BD Pharmingen) for 10 minutes, the cell suspensions were
incubated with lineage (Lin) antibodies (biotinylated CD45/CD31/TER119
and streptavidin-APC; 559971, 554067, BD), CD24-PE (553262, BD) and
CD49-FITC (555735, BD) for 20 minutes on ice. All cell sorts were
performed using FACSAria (Becton Dickinson), and gates were set
according to the isoform control antibody labeled with the corresponding
fluorochromes. The sorted cells were mixed with 100 l Matrigel mix [5%
FCS Epicult medium (Stem Cell Technologies) and 50% Matrigel] and
plated in Matrigel-coated 8-well chambers. After 8-10 days, the Matrigel
culture was fixed in 4% paraformaldehyde, transferred into HistoGel (HG-
4000-012, Thermo Scientific) and embedded in paraffin.
Statistical analyses
All comparisons were analyzed using two-tailed Student’s t-tests. P≤0.05
was defined as statistically significant. Values are given ± s.d.
RESULTS
Expression patterns of Id4 in mammary glands
We first surveyed the expression pattern of ID4 in mammary
glands during pubertal development. We used an Id4-knockout
mouse line (on the CD1 background) in which the lacZ reporter
cassette replaced 220 bp of exon 1 and most of the C-terminus of
the Id4 locus (Bedford et al., 2005). Using a -galactosidase assay
to stain whole-mount mammary glands of 6-week-old mice
heterozygous for this reporter gene, we observed -galactosidase
activity throughout the ductal tree, including the terminal end buds
(TEBs) (Fig. 1A). Specifically, staining was detected throughout
the cap cell layer of TEBs (Fig. 1B) and the basal cell layer of the
subtending ducts; staining was also detected in some of the body
cells and in a minor fraction of the luminal cell layer (Fig. 1B,C).
As expected, no -galactosidase staining was detected in mammary
glands from Id4 wild-type mice (insets in Fig. 1A,B).
Using immunohistochemical staining to detect ID4 in age-
matched wild-type CD1 mice, we confirmed ID4 expression in cap
and myoepithelial cells as well as in some of the body cells (Fig.
1D,E). However, no convincing signal was detected in luminal
epithelial cells. This is not surprising because this immunoassay is
less sensitive than the enzymatic reporter assay. Of note, we
confirmed the specificity of this antibody using mice that were
homozygous for the lacZ gene cassette and thus were null for Id4
(insets in Fig. 1D,E).











At 10 weeks of age, basal cells continued to produce ID4, and
numerous luminal cells also expressed ID4, based on -
galactosidase staining (Fig. 1F). The specificity of -galactosidase
staining was again confirmed by the lack of signal in age-matched
Id4 wild-type mice (inset in Fig. 1F). This expression pattern was
confirmed by immunohistochemical staining for ID4 in mammary
glands from 10-week-old wild-type mice (Fig. 1G).
Id4-null mice exhibit impaired mammary
development
To investigate the importance of Id4 in mammary development, we
first examined the #4 mammary glands from 6-week-old Id4-null
mice (CD1 strain) by whole-mount carmine staining. At this
developmental stage, the wild-type ductal tree filled 65±12% of the
fat-pad, whereas the Id4-null ductal tree occupied only 49±10%
(P<0.001; n5; Fig. 2A,B). The Id4-null ducts extended only
1.7±1.5 mm beyond the edge of lymph node, which is much less
than the wild-type ducts (7.9±1 mm) (Fig. 2A,C; P0.004).
Furthermore, whereas 27±6 side-branches per mm2 were observed
in wild-type glands, only 15±2 were found in Id4-null glands (Fig.
2A,D), constituting a significant reduction (P0.01). In addition,
whereas 17±4 TEBs were found in wild-type glands, only 10±5
were observed in Id4-null glands (P0.02; Fig. 2E). Heterozygous
glands were similar to those of wild-type mice in all four
measurements (Fig. 2B-E), suggesting that one copy of Id4 is
sufficient for ductal development.
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Fig. 1. Id4 is expressed in mammary cap cells, myoepithelial cells
and a subset of luminal epithelial cells. (A-C)-galactosidase
staining showing Id4 expression in mammary whole-mounts (A),
terminal end buds (TEBs) (B) and ducts (C) of 6-week-old Id4+/– mice
(CD1 strain). Insets show negative staining of Id4+/+ TEBs. Arrows
highlight stained cap cells and basal cells, and arrowheads body cells
and luminal cells. (D,E)Immunohistochemical staining of ID4 in TEBs (D)
and ducts (E) of 6-week-old Id4+/+ mice (CD1 strain). Insets show
negative staining of Id4–/– mammary TEBs and ducts. (F)-galactosidase
staining showing Id4 expression in mammary ducts of 10-week-old
Id4+/– mice (CD1 strain). Inset shows negative staining of Id4+/+ ducts.
(G) Immunohistochemical staining detecting ID4 in ducts in 10-week-
old Id4+/+ mice (CD1 strain). Inset shows negative staining of Id4–/–
ducts. 
Fig. 2. Impact of Id4 loss on mammary development. (A)Whole-
mounts of mammary glands from 6-week-old Id4+/+ and Id4–/– mice
(CD1 strain). On the right are higher magnification views of the boxed
areas. LN, lymph node. (B-E) Quantitative analysis of epithelial filling,
relative distance to lymph node, side-branches, and average number of
TEBs in whole-mounts of the indicated Id4 genotypes (n5). (F)Whole-
mounts and H&E sections of Id4+/+ and Id4–/– mammary glands at
pregnancy day 12. (G,H)Quantification of alveoli per mm2 or per
alveolar unit of Id4+/+ or Id4–/– mammary glands at pregnancy day 12












By H&E staining, subtending ducts in Id4-null glands appeared
normal; however, 18 of 50 TEBs in Id4-null mice (6 weeks)
appeared irregular: the cap cell layer was disorganized and
detached from the body cells (supplementary material Fig. S1A),
with stroma and collagen wrapping along these defective TEBs
(supplementary material Fig. S1A,B). Immunohistochemical
staining showed that the -smooth muscle actin (-SMA)-stained
cap cell layer was discontinuous and detached from the keratin 8-
positive body cell compartment (supplementary material Fig. S1A).
Keratin 8 and keratin 5 co-immunostaining confirmed this
phenotype (supplementary material Fig. S1B).
To determine whether this TEB defect was due to impaired cell
adhesion and migration, we first immunostained TEBs for several
cell adhesion markers, including E-cadherin (cadherin 1), P-
cadherin (cadherin 3), fibronectin and laminin, but failed to detect
any alteration in Id4-null glands (data not shown). Netrin 1 and its
receptor neogenin are crucial for cell migration, especially in the
nervous system, and ablation of the gene encoding either protein
results in disorganized TEBs (Srinivasan et al., 2003), which
appear similar to those in Id4-null glands. Therefore, we
investigated whether netrin 1 or neogenin expression was altered
in Id4-null TEBs. Immunohistochemical staining detected netrin 1
in wild-type TEBs (in the majority of body cells as well as the cap
cell layer) as reported (Srinivasan et al., 2003), but the intensity of
staining was diminished in Id4-null TEBs (supplementary material
Fig. S1C). Likewise, whereas neogenin was found in the cap cell
layer of wild-type TEBs, it was undetectable in the cap cell layer
of Id4-null TEBs (with the exception of the few cells in the space
between the cap cell and body cell compartments) (supplementary
material Fig. S1C).
By 10 weeks of age, the wild-type mammary ductal tree had
filled the entire fat-pad and TEBs had all regressed (supplementary
material Fig. S2A). However, ductal expansion in the Id4-null
gland was only 70% complete and was accompanied by fewer side-
branches (P0.02; supplementary material Fig. S2A-C); many
defective TEBs remained (supplementary material Fig. S2A). By
25 weeks of age, the Id4-null ductal tree had filled the entire fat-
pad and lost TEBs, but still contained significantly fewer side-
branches than the ductal tree in wild-type mice (P0.04;
supplementary material Fig. S2D,F). This reduced branching
morphogenesis persisted into pregnancy: alveoli density in Id4-
knockout glands was half that of wild-type glands (12 dpc; Fig. 2F-
H). By parturition, alveolar density was still lower in these
knockout glands than in wild-type glands. Nevertheless, functional
differentiation occurred normally in Id4-null glands: cytoplasmic
lipid droplets were observed in many alveolar cells and -casein
and WAP were detected at a similar level as in wild-type cells
(supplementary material Fig. S3A,B), indicating active milk
synthesis.
Next, we determined whether the developmental defects in Id4-
null mammary glands resulted from defective ductal cells per se or
from stromal or systematic abnormalities as a result of germline
deletion of Id4. We transplanted small mammary pieces (1-2 mm
in diameter) from 12- to 16-week-old wild-type and Id4-null mice
(n3; on the CD1 background) contralaterally into epithelium-
cleared #4 fat-pads in 3-week-old Rag1-null immunodeficient mice
(n16), and examined their outgrowths 8 weeks later. Whereas the
Id4 wild-type donors resulted in 72±27% fat-pad filling, the Id4-
null donors gave rise to only 38±32% filling. This reduction (47%)
is highly significant (P<0.001; supplementary material Fig. S4A).
Furthermore, side-branching was also significantly reduced
(supplementary material Fig. S4A).
Developmental phenotypes associated with a knockout strain are
also modulated by the genetic background, the reporter gene
cassette used in targeted gene ablation, and the immune system.
Therefore, we confirmed some of the above results using a
different line of Id4-knockout mice. This line is on the
129SV/C57BL6 background, has had most of the Id4 coding
sequence (exons 1 and 2) replaced by a GFP/neo gene cassette, and
also carries the transgenic allele of DsRed.T3 (Vintersten et al.,
2004), which helps visualize transplant outgrowth. Mammary
fragments from this line, as well as from Id4 wild-type DsRed.T3
transgenic littermate controls, were transplanted into cleared fat-
pads of syngeneic (and thus immune-intact) mice. The glands of
the recipient mice were analyzed by fluorescent imaging of the
ubiquitously expressed DsRed at different developmental stages: 5
and 10 weeks post-transplantation; days 5.5, 7.5, 8.5 and 14.5 of
pregnancy initiated at 6 weeks after transplantation; and lactation
day 1. At both 5 and 10 weeks post-transplantation, side-branching
was reduced in Id4-null epithelium in 12 of 18 and 6 of 6 mice,
respectively (supplementary material Fig. S4B). Likewise, at
pregnancy days 5.5-8.5, side-branching was reduced in Id4-null
epithelium in 11 of 23 mice. However, at pregnancy day 14.5 and
lactation day 1, Id4-null epithelium was indistinguishable from
wild-type tissue in 4 and 3 mice, respectively. This transplantation
experiment using a different knockout allele confirmed the role of
ID4 in branching morphogenesis. The lack of alveolar defects
during mid-pregnancy and early lactation in this line might be due
to a difference in the gene-targeting strategy, genetic background,
or systemic or stromal impact. For the remainder of this study, only
mice carrying the lacZ knock-in cassette was used.
Impaired mammary cell proliferation in Id4-null
mice
We tested whether reduced ductal and alveolar expansion in Id4-
null glands was caused by a reduction in cell proliferation. We first
compared TEBs and ducts between wild-type and Id4-null mice
(n4) at 6 weeks of age by immunohistochemical staining for BrdU
and Ki67 (Fig. 3A-C). BrdU incorporation into body cells of Id4-
null TEBs was similar to that of wild-type TEBs (P0.4; Fig. 3B),
but BrdU incorporation into cap cells of Id4-null TEBs was half
that of wild-type TEBs (P0.02; Fig. 3B). In ducts, however,
luminal epithelial cell proliferation was reduced by 33% as a result
of Id4 loss (P0.03; Fig. 3C,D), whereas myoepithelial
proliferation was unaltered (Fig. 3D).
To further test the proliferative impact of Id4 loss on luminal and
myoepithelial cells, we isolated by FACS the luminal (Lin– CD24+
CD49f–) and basal (Lin– CD24+ CD49f+) cell populations of 12-
week-old wild-type and Id4-null mammary glands and then
performed an in vitro colony assay in Matrigel (Stingl et al., 2006).
Luminal cells from Id4-null mice were defective in forming
colonies (P0.005; supplementary material Fig. S5A,B). In
accordance, fewer cells were positive for Ki67 in the Id4-null than
in the wild-type luminal colonies (P0.01; n3; supplementary
material Fig. S5C,D). Basal cells from both genotypes formed very
few and generally miniature colonies, which also showed very low
proliferation rates (supplementary material Fig. S5).
Moreover, we asked whether Id4 loss also affected cell
proliferation during alveolar expansion in pregnant animals. Ki67
staining was positive in 54±8% of mammary epithelial cells in
wild-type mid-pregnant mice, but in only 41±5% of the Id4-null
mammary cells (P0.04; n5; data not shown). We conclude that
ID4 promotes cell proliferation in mammary TEBs, ducts and
alveoli.











In addition, we tested whether these proliferative defects in Id4-
null mammary glands were due to an impaired proliferative response
to estrogen and/or progesterone signaling. Indeed, stimulation with
estrogen or progesterone induced significantly lower mammary cell
proliferation in ovariectomized Id4-null mice than in wild-type mice
(Fig. 3E,F). Likewise, stimulation with both hormones induced
significantly less proliferation in Id4-null mammary transplants than
in wild-type transplants (Fig. 3G). These data suggest that, in the
mammary ductal epithelium, ID4 maintains a normal proliferative
response to estrogen and progesterone. This transplantation
experiment also validated the epithelium-intrinsic role of ID4 in
regulating mammary development.
p38MAPK activation mediates cell cycle arrest in
Id4-null mammary glands
To investigate the molecular mechanism by which ID4 mediates a
normal proliferative response to estrogen and progesterone, we
used Luminex suspension antibody arrays to compare 65 proteins
in mammary total protein lysates extracted from 10-week-old wild-
type and Id4-null CD1 mice (n3). Only two proteins – PAI1
(serpine 1 – Mouse Genome Informatics) and phosphorylated
p38MAPK/ (T180/pY182; MAPK14/11 – Mouse Genome
Informatics) – were found to be significantly different (P<0.05)
between these two sets of lysates (Fig. 4A; supplementary material
S6). Since the absolute difference for PAI1 was small, only
p38MAPK/ (referred to as p38MAPK hereafter) was further
investigated. By immunohistochemical staining, we confirmed
p38MAPK activation: phospho-p38MAPK-positive cells were
much more readily detected in mature ducts and TEBs in Id4-null
mice than in wild-type mice at 4, 6 or 10 weeks of age (Fig. 4B;
supplementary material Fig. S7; n4 for each).
p38MAPK is known to block the cell cycle by phosphorylating
and stabilizing p21 (CDKN1A – Mouse Genome Informatics)
(Kim et al., 2002), by upregulating p16 (Cdkn2a) expression
(Bulavin et al., 2004), and by phosphorylating cyclin D1,
resulting in cyclin D1 ubiquitylation and proteosomal degradation
(Casanovas et al., 2000). Analysis of mammary gland RNA by
qPCR revealed that p21 and p16 were increased 3-fold in Id4-null
as compared with wild-type mammary glands (6 weeks of age;
n5; P0.02 and P0.04, respectively; supplementary material
Fig. S8A). In accordance, the p21 protein was detected in 2.5-fold
more cells in the TEBs of Id4-null versus wild-type mice
(3.0±1.1% versus 1.3±1.0%; P0.03; supplementary material Fig.
S8B,C), although it was undetectable in the ducts of either
genotype (data not shown). Likewise, whereas it was nearly
undetectable in wild-type TEBs and ducts, p16 was found in
approximately half of the cells in the TEBs and some epithelial
cells in the mature ducts of Id4-null mice (supplementary material
Fig. S8B; data not shown). In addition, fewer cyclin D1-positive
cells were found in Id4-null than wild-type TEBs (6.2±0.7%
versus 10.7±1.1%; P0.02; supplementary material Fig. S8D). As
expected, the mRNA level of cyclin D1 was unaffected by Id4
loss (n5; P0.79; supplementary material Fig. S8A).
Collectively, these experiments demonstrate that aberrant
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Fig. 3. Impact of Id4 loss on mammary cell
proliferation and hormone-induced
proliferation. (A-D)Proliferation in TEBs and
ducts at 6 weeks of age. Photomicrographs (A,C)
and quantitation (B,D) are shown. n4 mice (CD1
strain). Body cells and cap cells in TEBs are
outlined. (E,F)Quantitation of Ki67 staining of
mammary ducts. Ten-week-old ovariectomized
Id4–/– and Id4+/+ mice (CD1 strain) were treated
with vehicle (sesame oil), -estradiol-3-benzoate
(1g) or progesterone (1 mg) daily for 2 days.
Total ductal cells in at least ten 40 views were
counted for each mouse (n3). (G)Quantitation of
Ki67 staining of Id4–/– or Id4+/+ mammary
transplants (FVB strain) in mice that had been
injected daily with -estradiol-3-benzoate (1g)
and progesterone (1 mg) for 9 days. At least 1000
cells were counted for each section. n7












activation of p38MAPK in Id4-null mammary glands is
associated with alterations of its downstream components that are
known to regulate cell cycle progression.
To test whether p38MAPK activation has a causal role in the
reduced proliferation in Id4-null mammary glands, we used a
p38MAPK inhibitor to treat mice that had been transplanted with
Id4-null or wild-type mammary fragments and stimulated with
estrogen and progesterone. Daily treatment for 3 days with
SB203580 at 15 mg per kg body weight – a dosage reported to
suppress p38MAPK in mammary glands in vivo (Bulavin et al.,
2004) – did not affect the proliferation rate of wild-type
transplants (39.6±3.5% versus. 40.9±4.1% for the saline control;
Fig. 4C), suggesting that basal p38MAPK activity has little
effect on estrogen/progesterone-induced proliferation of normal
mammary glands. However, this treatment increased cell
proliferation of the Id4-null transplants from 20.9±4.3% to 36.5±
4.8% (P<0.001), a level similar to that in wild-type transplants
(40.9±4.1%; P0.53; Fig. 4C). As expected, SB203580-treated
Id4-null outgrowths had fewer cells positive for p21 (data not
shown) and p16 (supplementary material Fig. S8E), and more
cells positive for cyclin D1 (supplementary material Fig. S8F).
Since chemical inhibitors such as SB203580 may affect the
activity of other protein kinases, we repeated the above inhibitor
experiment using SB239063, which exhibits better p38MAPK
selectivity than SB203580 (Barone et al., 2001). Again, the level
of proliferation in Id4-null transplants was fully restored
(supplementary material Fig. S9A). Collectively, these data
suggest that p38MAPK activity is responsible for the reduction
in proliferation caused by Id4 loss.
Apoptosis induction in Id4-null mammary glands
is mediated by p38MAPK
ID proteins and p38MAPK have both been associated with the
regulation of cell survival; therefore, we asked whether an increase
in cell death contributes to the impaired mammary development of
Id4-null mice. Wild-type TEBs contained 1.6±0.5% apoptotic cells,
but the Id4-null TEBs harbored 3±1% (n5; P0.04; Fig. 5A,B).
Both wild-type and Id4-null mammary ducts in 6-week-old mice had
few apoptotic cells as determined by TUNEL staining (data not
shown). However, in mammary transplants treated with estrogen and
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Fig. 4. Id4 loss activates p38MAPK, and a p38MAPK inhibitor
restores cell proliferation in Id4–/– mammary glands. (A)Relative
p38MAPK levels in 10-week-old Id4+/+ and Id4–/– (CD1 strain) mouse
mammary lysates as measured by the Luminex bead assay. n3 each.
(B)Immunohistochemical staining for phospho-p38MAPK in mammary
glands of 10-week-old Id4+/+ and Id4–/– mice (CD1 strain). Both TEBs
and mammary ducts are shown. (C)Levels of proliferation in estrogen
and progesterone (E+P)-stimulated mammary epithelial transplants (FVB
strain) treated with the p38MAPK inhibitor SB203580. n7
transplanted mice. Error bars indicate s.d.
Fig. 5. Apoptosis induction in Id4–/– mammary gland is mediated
by p38MAPK. (A)TUNEL staining showing apoptosis in TEBs of 6-
week-old mice (CD1 strain). Id4 genotypes are indicated. Dotted line
highlights the TEB. (B) Levels of apoptosis as assessed by TUNEL
staining in A. At least 1000 cells were counted per section per mouse
(n5). (C)Levels of apoptosis in transplanted ductal outgrowths
stimulated with -estradiol-3-benzoate and progesterone. (D)Levels of
apoptosis in transplanted ductal outgrowths that were stimulated with
-estradiol-3-benzoate and progesterone and were also treated with












progesterone for 9 days, the wild-type ductal epithelium had
1.3±0.3% apoptotic cells, whereas the Id4-null epithelium contained
3.3±0.7% apoptotic cells (P<0.001; Fig. 5C). Collectively, these
observations suggest that ID4 plays a crucial role in maintaining cell
survival of both TEBs and the ductal epithelium.
Next, we tested whether p38MAPK also mediates apoptosis in
these Id4-null mammary cells. In the wild-type epithelium,
SB203580 or SB239063 had little effect on apoptosis; however, in
the Id4-null mammary epithelium, treatment with SB203580 or
SB239063 reduced the apoptotic rate from 3.4±0.9% to 2.1±1.0%
(P0.03) or from 1.8±0.3% to 0.8±0.1% (P0.004), respectively
(Fig. 5D; supplementary material S9B). These reduced apoptosis
rates are similar to those in the wild-type epithelium treated with
these inhibitors. We conclude that ID4 maintains mammary cell
survival by suppressing p38MAPK.
p38MAPK has been reported to stimulate apoptosis by
phosphorylating and activating BimEL (BCL2L11 – Mouse
Genome Informatics) (Cai et al., 2006), one of three gene products
of the Bim locus. Bim-knockout mice fail to activate apoptosis in
body cells, thus interfering with lumen clearing during pubertal
development (Mailleux et al., 2007). By immunohistochemical
staining, we found more pBimEL-positive cells in Id4-null than
wild-type TEBs (supplementary material Fig. S10A). As expected,
SB203580 treatment reduced the frequency of pBimEL-positive
cells in Id4-null mammary epithelium (supplementary material Fig.
S10B). These data suggest that p38MAPK-induced apoptosis in
Id4-ablated mammary cells is likely to occur by phosphorylation
and activation of BimEL.
Id4 knockdown leads to both p38MAPK activation
and p38MAPK-dependent apoptosis in cultured
mammary tumor cells
To further demonstrate ID4-mediated suppression of p38MAPK,
we performed siRNA-mediated knockdown of Id4 in cultured cells.
We have reported that Id4 is overexpressed in mammary tumors
from the MMTV-Wnt1 transgenic model of breast cancer (Huang
et al., 2005). We have since established a cell line, ZD2855, from
a tumor of this model, and confirmed ID4 protein expression in this
culture by western blotting (Fig. 6A). Transfection of two
independent siRNA oligos (Id4siRNA1 and Id4siRNA2) targeting
two different regions of Id4 mRNA achieved a significant
knockdown of ID4 in these cells within 48 hours, and the level of
its close family member ID2 did not compensatively rise (Fig. 6A).
Id4 knockdown with either Id4siRNA1 or Id4siRNA2 caused an
increase in the levels of phospho-p38MAPK (Fig. 6A). This
observation further established the ID4-mediated suppression of
p38MAPK activity.
We also tested whether this ID4-p38MAPK pathway regulates cell
proliferation and apoptosis in the ZD2855 cell line. At 48 and 72
hours post-transfection, cell numbers were much lower in the
Id4siRNA1-treated group than in both control siRNA- and mock-
transfected groups (P0.03; Fig. 6B). This difference in cell
expansion was not due to cell proliferation: no difference in BrdU
incorporation or cell cycle distribution was detected between control
siRNA- and Id4siRNA1-transfected cells 48 hours after transfection
(supplementary material Fig. S11; data not shown), and levels of
p21, p16 and cyclin D1 were also unaltered (data not shown).
5253RESEARCH ARTICLEID4 in mammary development
Fig. 6. Id4 is required for ZD2855
mammary tumor cell survival.
(A)Western blotting for the indicated
proteins in ZD2855 cells 48 hours post-
transfection with the indicated siRNA
oligos. (B)Cell growth as measured by
the MTS assay at 0, 24, 48 or 72 hours
after treatment with the indicated
siRNAs. *, P0.03, ConsiRNA-treated
versus Id4siRNA1-treated groups at 48
or 72 hours. (C)TUNEL staining of
ZD2855 cells 48 hours following
treatment with the indicated siRNAs.
(D)Quantitation of TUNEL-positive cells
among ZD2855 cells transfected with
the indicated siRNAs. PBS (control) or
SB203580 (10M) was added 12 hours
following transfection; after another 48
hours, TUNEL staining was performed.
(E)Western blotting for the indicated
proteins in ZD2855 cells 48 hours after
transfection with the indicated siRNAs.
(F)Quantitation of apoptosis in ZD2855
cells transfected with ConsiRNA or
Id4siRNA1, as well as with siRNA oligos
against the indicated genes. **,
P<0.01. The bar charts (B,D,F) show
data from three independent












However, Id4siRNA1-treated and control siRNA-treated cell cultures
exhibited a significant difference in apoptosis: very few apoptotic
cells were detectable in control siRNA-transfected cultures
(0.1±0.2%), whereas the number of apoptotic cells was 2.5±0.3% in
Id4siRNA1-transfected cultures (P<0.001; Fig. 6C,D). Collectively,
these observations suggest that ID4 maintains the viability of
transformed mammary cells, but does not affect their proliferation.
We next investigated whether this ID4-regulated tumor cell
survival was also mediated by p38MAPK activation. We
transfected ZD2855 cells with Id4siRNA1 and treated the culture
12 hours later with either PBS (control) or SB203580 (at a final
concentration of 10 M). After another 48 hours, we quantified the
apoptosis rate by TUNEL staining. SB203580 blocked apoptosis in
these cells by 66% (n3; P0.001; Fig. 6D), suggesting a crucial
role of p38MAPK in mediating apoptosis caused by Id4
knockdown. To confirm that the restoration of cell viability in these
SB203580-treated cells was indeed due to specific suppression of
p38MAPK, and not due to off-target effects of this inhibitor, we
transfected ZD2855 cells with ConsiRNA or Id4siRNA1, and
additionally with p38MAPKsiRNA or p38MAPKsiRNA, or
both. After 48 hours, we first confirmed the knockdown of ID4,
p38MAPK or p38MAPK by immunoblotting (Fig. 6E), and then
quantified apoptosis rates by TUNEL staining. Silencing
p38MAPK (Mapk14) or p38MAPK (Mapk11) or both suppressed
apoptosis in Id4-knockdown cells, down to levels comparable to
those seen in Id4 wild-type cells transfected with corresponding
p38MAPK siRNA oligos (Fig. 6F). This suppression of apoptosis
in Id4-knockdown cells was validated using another set of siRNA
oligos against different gene regions of p38MAPK and
p38MAPK (data not shown). Collectively, these data confirmed a
key role of p38MAPK in mediating mammary tumor cell apoptosis
caused by Id4 knockdown.
DISCUSSION
We found that Id4 is expressed in cap and basal cells as well as in
some of the luminal cells in the mammary gland. It partly mediated
proliferative responses to estrogen and progesterone signaling, and
promoted ductal elongation and branching morphogenesis. ID4
also maintained the survival of normal mammary cells as well as
cultured mammary tumor cells. These normal and tumorigenic
functions of ID4 were primarily achieved by suppressing
p38MAPK activity. This is the first report, to our knowledge,
linking the ID family of proteins to p38MAPK signaling.
During puberty, ID4 was expressed in the cap cell layer in TEBs
and the myoepithelium in subtending ducts, but was found only
sporadically in body cells and luminal epithelial cells. In more
mature mammary glands, ID4 continued to be expressed in the
myoepithelium, and it was also more frequently detected in the
luminal cell population. Using two independent knockout lines and
transplantation experiments, we demonstrated that Id4 loss caused
numerous developmental defects in the mammary gland, including
impairments in ductal elongation, side-branching and possibly
alveologenesis (Fig. 2; supplementary material Figs S2, S3). ID4
appears to be required for the proliferation of cap cells, but not
body cells, in TEBs (Fig. 3B). By contrast, ID4 seems to be
required for the proliferation of luminal epithelial cells, but not
myoepithelial cells, in the subtending ducts (Fig. 3D). The role of
ID4 in supporting luminal cell proliferation in more mature ducts
was confirmed by an in vitro colony assay using isolated luminal
cells (supplementary material Fig. S5), which also established
luminal cell-autonomous functions of ID4. Furthermore, we found
that ID4 is required for increased mammary cell proliferation in
response to estrogen, progesterone, or both (Fig. 3E-G). Id4 has
been reported to be transcriptionally activated by ectopically
expressed progesterone receptor in cultured mammary epithelial
cells (Fernandez-Valdivia et al., 2008); therefore, ID4 might be an
important mediator of cell proliferation induced by progesterone,
adding to the small number of genes, such as RANKL (Tnfsf11),
Elf5 and Wnt4, that have also been reported to mediate
progesterone signaling in branching morphogenesis and
alveologenesis (Brisken and Rajaram, 2006). Although ID4 partly
mediated ductal cell proliferation induced by estrogen signaling,
Id4 does not seem to be a direct transcriptional target of estrogen
receptor because: (1) Id4 is expressed in basal cells, which lack
estrogen receptor; (2) there is no estrogen-response motif in the
promoter region of the Id4 gene (data not shown); and (3) in MCF7
breast cancer cells, Id4 is neither induced nor inhibited by estradiol
(Beger et al., 2001) (Adrian Lee, personal communication), and is
inversely correlated with estrogen receptor in human breast cancer
(de Candia et al., 2006; Roldan et al., 2006). We postulate that ID4
functions via suppression of p38MAPK to maintain low levels of
the cell cycle inhibitors p21 and p16 and elevated levels of cyclin
D1, allowing cells to undergo a proper proliferative response to
estrogen-induced cell cycle stimulators arising in cis or via
paracrine signaling from a neighboring estrogen receptor+ cell.
Besides regulating the proliferation of cap cells, ID4 also has an
important role in the proper organization of TEBs and their
penetration of the fat-pad, as Id4-null TEBs exhibited cap cell
detachment and stromal condensation (supplementary material Fig.
S1). The disorganized TEBs are reminiscent of those found in
netrin 1 or neogenin knockout mice (Srinivasan et al., 2003), or in
mice lacking Slit2 or its receptor Robo1 (Strickland et al., 2006).
We have confirmed reduced protein expression of netrin 1 or its
receptor neogenin in Id4-null TEBs (supplementary material Fig.
S1C), suggesting that ID4 might regulate TEB organization
through netrin-neogenin signaling. Of note, although members of
the ID family have been reported to regulate stem cells in several
other tissues by preventing premature differentiation (Perk et al.,
2005), the structural and proliferative defects of TEBs, as well as
the proliferative blockade of more mature ducts in these Id4-null
mice, were unlikely to be the result of a dysfunctional stem cell
population: we did not detect a defect in either primary or
secondary mammosphere-forming potential in Id4-null primary
mammary cells when compared with wild-type mammary cells
(supplementary material Fig. S12). Furthermore, ID4-mediated
regulation of TEB organization and migration does not appear to
originate from its role in mediating hormone signaling, as these
defects were not observed in mice deficient for estrogen receptor
or progesterone receptor (Lydon et al., 1995; Bocchinfuso et al.,
2000; Feng et al., 2007).
p38MAPK activity was increased in Id4-null mammary glands
compared with wild-type glands (Fig. 4; supplementary material Figs
S6, S7). Suppression of p38MAPK by pharmacological inhibitors
reversed the proliferation and survival defects caused by Id4 loss
during normal mammary development (Fig. 4; supplementary
material Fig. S9), and the suppression of p38MAPK by either
pharmacological inhibitors or siRNA reversed the survival defects
caused by Id4 loss in transformed mammary cells (Fig. 6). We
conclude that ID4-mediated suppression of p38MAPK is necessary
for the pro-proliferation and anti-apoptosis functions of ID4 in
normal mammary glands and for the anti-apoptosis role in
transformed mammary cells. These findings are consistent with a
recent report that p38MAPK is required for anoikis and lumen
formation during mammary development (Wen et al., 2011), and











with earlier studies linking p38MAPK to both cell cycle arrest and
apoptosis induction in several other tissues (Thornton and Rincon,
2009).
p38MAPK is known to control cell proliferation and apoptosis
by modulating a number of downstream factors. We found that the
p38MAPK targets p16, p21 and cyclin D1 were altered in Id4-null
mammary glands, and that these alterations were reversed in
mammary glands treated with the p38MAPK inhibitor SB203580
(supplementary material Fig. S8). As crucial cell cycle regulators,
these targets are likely to play a key role in mediating p38MAPK-
mediated anti-proliferation. Of note, the p21 and p16 promoters
harbor the bHLH-binding E box motif and have been reported to
be responsive to bHLH proteins (Prabhu et al., 1997; Zheng et al.,
2004); therefore, unrestrained activity of tissue-specific bHLH
proteins as a result of Id4 loss might also contribute to the aberrant
levels of p21 and p16 in Id4-null mammary glands. However, this
contribution seems to be minor because p21 and p16 levels in these
Id4-null mammary cells were highly responsive to a p38MAPK
inhibitor (supplementary material Fig. S8E,F) and because
proliferation of these Id4-null cells was completely restored by a
p38MAPK inhibitor (Fig. 4C; supplementary material S9A).
BimEL is a major downstream target of p38MAPK that is
implicated in apoptosis. Bim is required for apoptosis in TEBs,
which allows lumen clearing during pubertal development (Mailleux
et al., 2007). We found that BimEL was activated in Id4-null
mammary glands, and that treatment of these glands with the
p38MAPK inhibitor SB203580 blocked BimEL activation
(supplementary material Fig. S10) and also reversed excessive
apoptosis in TEBs. Collectively, these data suggest that high levels
of apoptosis in Id4-null TEBs are likely to be due to disproportionate
activation of p38MAPK-BimEL. However, in transformed
mammary cells, BimEL does not appear to play a significant role in
mediating p38MAPK-induced apoptosis. pBimEL was not activated
following Id4 knockdown-mediated p38MAPK activation in
ZD2855 mammary tumor cells (data not shown). Furthermore,
ConsiRNA- and Id4siRNA-treated ZD2855 mammary tumor cells
did not exhibit differences in the levels of p53 and FOXO3 (data not
shown), which have also been reported to mediate p38MAPK-
induced apoptosis (Cai et al., 2006; Cai and Xia, 2008). Therefore,
it is not yet clear how Id4 loss and the associated p38MAPK
activation cause apoptosis in these mammary cancer cells.
In conclusion, in this in vivo study we discovered that ID4
stimulates the proliferation of mammary epithelium during puberty,
pregnancy, and under stimulation by estrogen or progesterone or
both, and that it maintains the survival of normal and cancerous
breast cells. ID4 exerts these functions primarily through
suppressing p38MAPK activity. Therefore, blocking the
prosurvival function of ID4 or protecting p38MAPK activity might
be important in breast cancer prevention and treatment.
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